Success Stories: EB2-NIW Approved for a Vietnamese Clinical Translational Researcher in Oncology Following a Successful Request for Evidence (RFE) Response
Client’s Testimonial:
“Chen Immigration turned a challenging RFE into a successful outcome. Their professionalism and understanding of research-driven petitions exceeded my expectations. I am grateful for their work.”
On April 24th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Researcher in the Field of Oncology (Approval Notice).
General Field: Oncology
Position at the Time of Case Filing: Clinical Translational Researcher
Country of Origin: Vietnam
Country of Residence at the Time of Filing: Vietnam
Approval Notice Date: April 24th, 2025
Processing Time: 4 months and 19 days (Premium Processing Requested)
Case Summary:
North America Immigration Law Group (NAILG) is proud to announce the approval of an I-140 petition under the National Interest Waiver (NIW) category for a physician-scientist specializing in oncology and personalized medicine from Vietnam. He holds an M.D. and a Ph.D. in personalized medicine and clinical pharmacology and has substantial clinical experience. He has previously practiced medicine, which enhances his ability to translate complex pharmacological modeling into patient-centered therapeutic interventions. He later transitioned into research focused on precision oncology. Focused on precision medicine, our client’s work integrates multi-omics approaches and population pharmacokinetic modeling to develop and optimize individualized cancer therapies - efforts that directly address critical healthcare priorities in the United States. His petition, submitted through the direct premium processing, was approved after the successful submission of a Request for Evidence (RFE), underscoring both the significance of his research and the strength of our strategic response.
A Research Focus That Aligns with National Health Priorities
Our client’s research centers on advancing personalized oncology through an integrated approach that combines multi-omics analysis for biomarker discovery, population pharmacokinetic modeling to optimize cancer therapy, and the implementation of model-informed precision dosing strategies. His work also emphasizes the clinical translation and dissemination of these innovations to real-world settings. By addressing critical gaps in therapeutic individualization, his research directly supports national priorities in biomedical innovation, pharmacological modeling, and precision medicine.
Key Accomplishments Demonstrating Exceptional Merit
The client’s impressive research record and professional contributions demonstrate his extraordinary ability:
- Authored 6 peer-reviewed journal articles, including 1 first-authored publication, in highly respected scientific journals.
- Accumulated 203 citations, reflecting the broad scholarly influence and impact of his research.
- Secured competitive research funding from internationally recognized funding bodies, demonstrating both the relevance and value of his work.
- Contributed to widely referenced publications, with 4 papers ranked among the top 10% to 20% most-cited articles in Clinical Medicine for their publication years.
Thorough Handling of Request for Evidence
A Request for Evidence (RFE) was issued during the process, and North America Immigration Law Group (NAILG) prepared a thorough and effective response that ensured a favorable outcome.
Premium Processing Enables Swift Petition Approval
Thanks to the use of the premium processing, USCIS approved the petition just 26 business days after receiving the RFE response, reflecting the strength of the client’s qualifications and the quality of the petition.
NAILG congratulates our client on this well-earned achievement and looks forward to his continued advancements in oncology and personalized medicine.